Sageworth Trust’s Myriad Genetics MYGN Stock Holding History

Sageworth Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-320	Closed	-$7.43K	–	306
2023 Q1	$7.43K	Buy	+320	New	+$6.5K	﹤0.01%	322
2022 Q1	–	Sell	-69	Closed	-$2K	–	621
2021 Q4	$2K	Sell	69 -231	-77%	-$6.69K	﹤0.01%	615
2021 Q3	$10K	Hold	300	–	–	﹤0.01%	556
2021 Q2	$9K	Buy	+300	New	+$8.67K	﹤0.01%	619

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sageworth Trust's MYGN Position: Q2 2023 in Review

Sageworth Trust sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 320 shares — an estimated $7.43K sold.

Sageworth Trust first reported a position in MYGN in Q2 2021 and held it in 4 quarters. The position peaked at $10K in Q3 2021. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

Sageworth Trust reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
Sageworth Trust sold 320 Myriad Genetics shares in Q2 2023, an estimated $7.43K.
Sageworth Trust first reported a position in Myriad Genetics in Q2 2021 and held it in 4 quarters.
Sageworth Trust's Myriad Genetics position peaked at $10K in Q3 2021.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Sageworth Trust's 13F filing for Q2 2023, filed 26 Jul 2023.